Inductive Bio launches Indy, an AI assistant for medicinal chemists

New York drug-discovery startup Inductive Bio said it launched Indy, an AI chemistry assistant built with medicinal chemists, computational chemists, and DMPK scientists for partner programs. The company says Indy QCs assay data, reads structure-activity relationships, runs generative chemistry and FEP setups, and builds project slides — and that in a head-to-head on 84 real dose-response curves Indy scored 89% accuracy versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol (company claim).

Specialized AI agents are moving into high-stakes chemistry work — checking lab assays, reading how a molecule’s shape changes what it does, and lining up what to synthesize — not just chatbot brainstorming. A same-day company launch claims large gains over general chatbots on real program data; that score is Inductive’s benchmark, not an independent audit.

Inductive Bio, a New York drug-discovery startup, said via PR Newswire on 14 Sep 2026 at 11:00 ET that it launched Indy, an AI chemistry assistant now available to partners. The company also calls Indy a medicinal chemistry agent. Medicinal chemistry, in plain English, is the work of designing drug-like molecules. That company release is the filing event. These are company claims. This desk did not test the software.

Inductive’s medicinal chemists, computational chemists, and DMPK scientists built Indy for their work inside partner programs, the company said. DMPK means drug metabolism and pharmacokinetics — how a body absorbs, breaks down, and clears a compound. Computational chemists model molecules on computers. The company said Indy has doubled the team’s productivity in those partner programs. File the doubled-productivity line as Inductive’s. This desk did not audit partner hours.

Indy, the company said, parses CRO reports, QCs every dose-response curve, interprets historical SAR, runs generative chemistry algorithms, sets up FEP calculations, and generates project-update slides. A CRO, or contract research organization, is an outside lab hired to run experiments. QC is quality control — checking whether an assay result is trustworthy. SAR, or structure-activity relationship, is how changing a molecule’s shape changes what it does. FEP, or free-energy perturbation, is a physics-style computer estimate of how tightly a molecule binds. Generative chemistry means proposing new molecule ideas. File those workflows as company product claims.

In a head-to-head the company published the same day, Indy scored 89% accuracy on 84 dose-response curves from real programs, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol, even when those general models were told to use the highest effort. A dose-response curve shows how a biological effect changes as you raise the dose. File 89 / 48 / 39 and the 84-curve set as Inductive’s benchmark. This is a company comparison, not an independent audit.

Nicholas Perl, PhD, head of chemistry at Anvia Therapeutics, said his team has incorporated Indy into data QC, SAR table construction and analysis, and synthesis queue management. Quoted, via the company release: “Indy surfaces patterns in the data that help us make better decisions, and it lets me spend less time maintaining slides and more time driving scientific strategy.” File the quote as his. This desk is not saying Anvia’s queues were independently timed.

Josh Haimson, co-founder and CEO of Inductive Bio, said the company trained Indy on the tasks that take medicinal chemists’ time but not their creativity. Quoted: “The result is an assistant that can double a chemist’s productivity while fitting seamlessly into their existing workflows.” File the doubling line as his. This desk is not saying Indy replaces chemists.

Company-site context only, not a new financing PR: Inductive markets virtual chemistry labs, Beacon-1 ADMET models, and Compass, a virtual lab bench. ADMET means absorption, distribution, metabolism, excretion, and toxicity — how a body handles a drug and whether it looks safe. The company says it already powers dozens of active discovery programs and leads a $21 million ARPA-H toxicity project with Amgen. ARPA-H is a U.S. health-research agency. File those as existing company-site lines. This filing is the Indy product launch only. This desk is not inventing a valuation, a Series round, or FDA clearance for Indy.

CONFIRMED here: Inductive Bio’s 14 Sep 2026 PR Newswire release at 11:00 ET — PRIMARY company source. The 89 / 48 / 39 dose-response scores are a company benchmark, not an independent audit. NOT claimed: independently verified productivity gains, a new financing round, a valuation, FDA clearance for Indy, that this desk tested the assistant, a stock tip, or investment advice. Distinct from the already-filed nara-health-14m, tandem-health-100m-series-b, ataraxis-tau-chemo, oracle-health-clinical-ai-agent-nurses, and beta-bionics-mint-fda.